A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on the QTc Interval.

Inclusion Criteria: * Male or female between 18 and 65 years of age inclusive * Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin ≤ 1.5x Upper limit of normal (ULN) * Healthy as determined by a physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. * A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal . Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods. Those of child-bearing potential must agree to use one of the protocol contraception methods. * Body mass index (BMI) within the range 18.5-29.0 kg/m2 (inclusive) * Capable of giving written informed consent * Current non-smokers who have not used tobacco products in the 6 month period preceding screening * No significant abnormality on 12-lead electrocardiogram (ECG) at screening * A 24 hour Holter ECG at screening that demonstrates no clinically significant abnormalities Exclusion Criteria: * A physician deems the subject unsuitable for the study * A screening Holter ECG tracing that reveals clinically concerning arrhythmias * A blood pressure that is persistently higher than 140/90 millimetres of mercury (mmHg) at screening. * A mean heart rate outside the range 40-90 beats per minute (bpm) at screening. * History or presence of any medically significant disease, or any disorder. In particular, a family history of QT prolongation, of early or sudden cardiac death or of early cardiovascular disease. * A positive result for Hepatitis B or Hepatitis C within 3 months of screening * Current or chronic history of liver disease, or known hepatic or biliary abnormalities * A positive pre-study drug/alcohol screen * A positive test for Human Immunodeficiency Virus (HIV) antibody * History of regular alcohol consumption within 6 months of the study * The subject has participated in a clinical trial and has received an investigational product within 3 months of the first dosing day in the current study * Exposure to more than four new chemical entities within 12 months prior to the first dosing day * Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements from 14 days before screening until the follow-up visit unless permitted by the investigator * History of sensitivity to any of the study medications * Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 3 month period * Pregnant females * Lactating females * Unwillingness or inability to follow the procedures outlined in the protocol * Subject is mentally or legally incapacitated